Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis
An Adaptive Enrichment Designed, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anshen Buxin Liuwei Pills in the Treatment of Cardiac Neurosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Lihong Ma, Prof
- Phone Number: 13811695093
- Email: mlh8168@163.com
Study Contact Backup
- Name: Yue Lan
- Phone Number: 13811695093
- Email: fuwaiyueyue@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Recruiting
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yue Lan
- Phone Number: 13811695093
- Email: fuwaiyueyue@163.com
-
Contact:
- Lihong Ma, Prof.
- Phone Number: 13811695093
- Email: mlh8168@163.com
-
-
Henan
-
Nanyang, Henan, China, 473010
- Recruiting
- Nanyang First People's Hospital
-
Contact:
- Jinxia Ma, Prof
- Phone Number: 0377-63310089
- Email: nysgcp@163.com
-
Xinxiang, Henan, China, 453000
- Recruiting
- The Third Affiliated Hospital of Xinxiang Medical University
-
Contact:
- Guotian Yin, Prof
- Phone Number: 0373-3029611
- Email: xysfygcp@163.com
-
-
Hunan
-
Changsha, Hunan, China, 410021
- Recruiting
- The First Hospital of Hunan University of Chinese Medicine
-
Contact:
- Jianhe Liu, Prof.
- Phone Number: 17343602090
- Email: ljhm1@163.com
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China, 010010
- Recruiting
- Inner Mongolia International Mongolian Hospital
-
Contact:
- Dalai Nashun, M.D.
- Phone Number: 13848913897
- Email: 1045321506@qq.com
-
-
Jiangsu
-
Kunshan, Jiangsu, China, 215300
- Recruiting
- Kunshan First People's Hospital
-
Contact:
- Haojun Xu, master
- Phone Number: 0512-57530744
- Email: 15062680097@163.com
-
-
Shandong
-
Jinan, Shandong, China, 250001
- Withdrawn
- The Second Affiliated Hospital of Shandong University of Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years old, ≤75 years old;
- Meet the diagnostic criteria for cardiac neurosis: the patient has palpitations, precordial pain, chest tightness, shortness of breath, dyspnea, dizziness, insomnia and dreaminess, cold hands and feet, hyperhidrosis and other cardiovascular symptoms and neurological disorders;
- Meet the diagnostic criteria of Heyisheng type palpitations in Mongolian medicine;
- There is no objective diagnosis of coronary heart disease (in accordance with any of the following): ①The activity flat test is negative; ② Coronary angiography or coronary CTA suggests that the lumen stenosis is ≤50%; ③ Exercise or drug load radionuclide examination results suggest no myocardial ischemia;
- The patient did not take anti-anxiety and depression drugs or psychotropic drugs within 2 weeks before enrollment;
- agrees to voluntarily participate in the study and signs an informed consent form .
Exclusion Criteria:
- Accompanied by organic heart disease, severe cardiopulmonary insufficiency;
- Poor hypertension control (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after treatment);
- Those with malignant arrhythmia;
- Those who use pacemakers;
- Patients with hyperthyroidism;
- Combined with severe liver and kidney damage (ALT, AST or TBIL> 2 times the upper limit of the normal reference value, or Cr> 1.5 times the upper limit of the normal reference value);
- People with serious primary diseases such as hematopoietic system or mental illness;
- SAS≥70;
- SDS≥73;
- Accompanying any other serious diseases or conditions such as malignant tumors;
- Women during pregnancy and lactation;
- People with allergies or allergies to the known ingredients of the research drug;
- Participated in other clinical research in the past 3 months;
- According to the judgment of the investigator, the subject is not suitable for research observation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Anshen Buxin Liuwei Pills
15 pills/time, 2 times/day, orally,for 8 weeks
|
15 capsules/time, 2 times/day, orally.
|
|
Placebo Comparator: Placebo
15 pills/time, 2 times/day, orally.
for 8 weeks
|
Placebo simulated as the Anshen Buxin Liuwei Pills with same appearance,smell and taste,15 capsules/time, 2 times/day, orally.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Palpitation with Heyisheng Type Symptoms Scale in Mongolian Medicine
Time Frame: 8 weeks
|
The scale is to record the symptoms of palpitation with Heyisheng Type in Mongolian Medicine, which is also usually seen in cardiac neurosis.
This scale includes two domain: the primary symptoms and the secondary symptoms.
The domain of the primary symptoms includes palpitations, chest tightness, chest pain, insomnia, and restlessness using the evaluating 4-Grade scales (Normal:0; Mild:3; Moderate:6 and Severe:9), while the domain of the secondary symptoms includes dizziness, like to sigh, easy to startle, tinnitus, blurred vision, fatigue, sweating, irritability, using the evaluating 4-Grade scales (Normal:0; Mild:1; Moderate:2 and Severe:3).
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac autonomic nervous function
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
The cardiac autonomic nervous function was evaluated by detecting the difference in heart rate per minute between standing and lying positions using RR interval in lead Ⅱ ECG.
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
Cardiac Neurosis Symptom Self-rating Scale
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
This self-rating scale was used to evaluate the main symptoms in cardiac neurosis, including palpitations, chest tightness, chest pain, hyperhidrosis, insomnia, irritability, with each symptom evaluated via a 4-grading scale (normal:0 points, mild: 1 point, moderate: 2 points, severe:3 points
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
Self-rating depression scale (SDS)
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
The Self-Rating Depression Scale (SDS) which was designed by Zung was adopted to assess participants' symptoms of depression during the past week.
The SDS assesses depressive symptoms on a four-point scale ranging from "a little of the time" (value = 1) to "most of the time" (value = 4).
The standard score is equal to the integer portion of 1.25 times the total score.
The standard score of SDS is interpreted as: normal (≤52), mild (53-62), moderate (63-72), and severe (≥73).
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
Self-rating Anxiety Scale (SAS)
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
The SAS is a 20-item measure developed to assess the frequency of anxiety symptoms based on diagnostic conceptualizations.
It consists primarily of somatic symptoms.
The respondent indicates how often he or she has experienced each symptom on a 4-point Likert scale consisting of "one or a little of the time" (coded as 1), "some of the time" (coded as 2), "good part of the time" (coded as 3), and "most or all of the time" (coded as 4).
Items 5, 9, 13, 16, and 19 are reversed scored and total scores on the SAS range from 0 to 80.
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
Pittsburgh Sleep Scale Score
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
The PSQI comprises 19 self-evaluation items, among which 18 items generate 7 components.
Each component is graded from 0 to 3, and the cumulative score of each component is the total score of PSQI, which ranges from 0 to 21.
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
Consumption of estazolam
Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
If the patient has a moderate or above anxiety and depression state and is intolerable, he could be given a short-term sedative and hypnotic drug,estazolam, and the frequency and dose of estazolam should be recorded in the patient's diary
|
Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks.
|
|
hypersensitive C-reactive protein (hs-CRP)
Time Frame: Baseline, 4 weeks, 8 weeks
|
hs-CRP is used to evaluate the level of systemic inflammation in the patients with cardiac neurosis.
|
Baseline, 4 weeks, 8 weeks
|
|
The level of serotonin
Time Frame: Baseline, 4 weeks, 8 weeks
|
The decrease of serotonin is reported in the patients with cardiac neurosis.
The level of serotonin could be used to evaluate the effect for cardiac neurosis.
|
Baseline, 4 weeks, 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ASBXLWW V2.0
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.